PFIZER INC Revenue Breakdown
No Revenue Breakdown for PFE on this site yet.
- 2025-12-31: Others Not split by product in the filing$62.58B100.00%; Total revenue $62.58B.
- 2024-12-31: Others Not split by product in the filing$63.63B100.00%; Total revenue $63.63B.
- 2023-12-31: Others Not split by product in the filing$50.91B100.00%; Total revenue $50.91B.
- 2022-12-31: Others Not split by product in the filing$91.79B100.00%; Total revenue $91.79B.
Source checked: the stored Revenue Breakdown page for PFE.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $62.58B 100.00% | $62.58B |
| 2024-12-31 | Not split by product in the filing $63.63B 100.00% | $63.63B |
| 2023-12-31 | Not split by product in the filing $50.91B 100.00% | $50.91B |
| 2022-12-31 | Not split by product in the filing $91.79B 100.00% | $91.79B |
| 2021-12-31 | Not split by product in the filing $73.64B 100.00% | $73.64B |
| 2020-12-31 | Not split by product in the filing $41.65B 100.00% | $41.65B |
| 2019-12-31 | Not split by product in the filing $40.91B 100.00% | $40.91B |
| 2018-12-31 | Not split by product in the filing $40.83B 100.00% | $40.83B |
| 2017-12-31 | Not split by product in the filing $52.55B 100.00% | $52.55B |
| 2016-12-31 | Not split by product in the filing $52.82B 100.00% | $52.82B |
| 2013-12-31 | Not split by product in the filing $51.58B 100.00% | $51.58B |
| 2012-12-31 | Not split by product in the filing $54.66B 100.00% | $54.66B |
| 2011-12-31 | Not split by product in the filing $61.03B 100.00% | $61.03B |
| 2010-12-31 | Not split by product in the filing $65.17B 100.00% | $65.17B |
| 2009-12-31 | Not split by product in the filing $49.27B 100.00% | $49.27B |
| 2008-12-31 | Not split by product in the filing $48.30B 100.00% | $48.30B |
| 2007-12-31 | Not split by product in the filing $48.42B 100.00% | $48.42B |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-06-28 | Not split by product $15.03B 100.00% | $15.03B |
| 2026-03-29 | Not split by product $14.45B 100.00% | $14.45B |
| 2025-12-31 | Not split by product $17.56B 100.00% | $17.56B |
| 2025-09-28 | Not split by product $16.65B 100.00% | $16.65B |
| 2025-06-29 | Not split by product $14.65B 100.00% | $14.65B |
| 2025-03-30 | Not split by product $13.71B 100.00% | $13.71B |
| 2024-12-31 | Not split by product $17.76B 100.00% | $17.76B |
| 2024-09-29 | Not split by product $17.70B 100.00% | $17.70B |
| 2024-06-30 | Not split by product $13.28B 100.00% | $13.28B |
| 2024-03-31 | Not split by product $14.88B 100.00% | $14.88B |
| 2023-12-31 | Not split by product $14.57B 100.00% | $14.57B |
| 2023-10-01 | Not split by product $13.49B 100.00% | $13.49B |
| 2023-07-02 | Not split by product $13.01B 100.00% | $13.01B |
| 2023-04-02 | Not split by product $18.49B 100.00% | $18.49B |
| 2022-12-31 | Not split by product $15.75B 100.00% | $15.75B |
| 2022-10-02 | Not split by product $22.64B 100.00% | $22.64B |
| 2022-07-03 | Not split by product $27.74B 100.00% | $27.74B |
| 2022-04-03 | Not split by product $25.66B 100.00% | $25.66B |
| 2021-12-31 | Not split by product $16.19B 100.00% | $16.19B |
| 2021-10-03 | Not split by product $24.04B 100.00% | $24.04B |
| 2021-07-04 | Not split by product $18.90B 100.00% | $18.90B |
| 2021-04-04 | Not split by product $14.52B 100.00% | $14.52B |
| 2020-12-31 | Not split by product $11.43B 100.00% | $11.43B |
| 2020-09-27 | Not split by product $10.28B 100.00% | $10.28B |
| 2020-06-28 | Not split by product $9.86B 100.00% | $9.86B |
| 2020-03-29 | Not split by product $10.08B 100.00% | $10.08B |
| 2019-12-31 | Not split by product $1.84B 100.00% | $1.84B |
| 2019-09-29 | Not split by product $12.68B 100.00% | $12.68B |
| 2019-06-30 | Not split by product $13.26B 100.00% | $13.26B |
| 2019-03-31 | Not split by product $13.12B 100.00% | $13.12B |
| 2018-12-31 | Not split by product $1.16B 100.00% | $1.16B |
| 2018-09-30 | Not split by product $13.30B 100.00% | $13.30B |
| 2018-07-01 | Not split by product $13.47B 100.00% | $13.47B |
| 2018-04-01 | Not split by product $12.91B 100.00% | $12.91B |
| 2017-12-31 | Not split by product $13.70B 100.00% | $13.70B |
| 2017-10-01 | Not split by product $13.17B 100.00% | $13.17B |
| 2017-07-02 | Not split by product $12.90B 100.00% | $12.90B |
| 2014-06-29 | Not split by product $12.77B 100.00% | $12.77B |
| 2014-03-30 | Not split by product $11.35B 100.00% | $11.35B |
| 2013-12-31 | Not split by product $13.56B 100.00% | $13.56B |
| 2013-09-29 | Not split by product $12.64B 100.00% | $12.64B |
| 2013-06-30 | Not split by product $12.97B 100.00% | $12.97B |
| 2013-03-31 | Not split by product $12.41B 100.00% | $12.41B |
| 2012-12-31 | Not split by product $13.89B 100.00% | $13.89B |
| 2012-09-30 | Not split by product $12.95B 100.00% | $12.95B |
| 2012-07-01 | Not split by product $13.97B 100.00% | $13.97B |
| 2012-04-01 | Not split by product $14.88B 100.00% | $14.88B |
| 2011-12-31 | Not split by product $11.92B 100.00% | $11.92B |
| 2011-10-02 | Not split by product $16.61B 100.00% | $16.61B |
| 2011-07-03 | Not split by product $16.98B 100.00% | $16.98B |
| 2011-04-03 | Not split by product $16.50B 100.00% | $16.50B |
| 2010-12-31 | Not split by product $14.92B 100.00% | $14.92B |
| 2010-10-03 | Not split by product $15.99B 100.00% | $15.99B |
| 2010-07-04 | Not split by product $17.13B 100.00% | $17.13B |
| 2010-04-04 | Not split by product $16.58B 100.00% | $16.58B |
| 2009-12-31 | Not split by product $15.80B 100.00% | $15.80B |
| 2009-09-27 | Not split by product $11.62B 100.00% | $11.62B |
| 2009-06-28 | Not split by product $10.98B 100.00% | $10.98B |
| 2009-03-29 | Not split by product $10.87B 100.00% | $10.87B |
| 2008-12-31 | Not split by product $12.35B 100.00% | $12.35B |
| 2008-09-28 | Not split by product $11.97B 100.00% | $11.97B |
| 2008-06-29 | Not split by product $12.13B 100.00% | $12.13B |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |